Since we demonstrated that inhibition of TLR2 and 4 in PBMCs blunted leptin secretion in response to HMGB1, this cytokine might be considered a new target to reduce pro-inflammatory response in T2DM and its related conditions. The gene discussed is HMGB1; the disease is type 2 diabetes mellitus.